AstraZeneca has reported that Lynparza (olaparib) in combination with abiraterone succeeded in a phase II trial by delaying disease progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
Novartis has reported positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer.
Syndax Pharmaceuticals and Nektar Therapeutics have entered into a non-exclusive immuno-oncology clinical trial collaboration.
The Combinations Alliance, a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network based at University of Birmingham, has launched a clinical trial testing a new treatment combination in patients with leukaemia.
Janssen has commenced a phase 1b/2 clinical development program to assess JNJ-68284528 (developed based on Legend’s LCAR-B38M), a chimeric antigen receptor T cell (CAR-T) therapy directed against B cell maturation antigen (BCMA), in patients with relapsed or refractory multiple myeloma.
Roche said that its cancer immunotherapy Tecentriq (atezolizumab) in combination with chemotherapy as first-line of treatment improved survival of patients with advanced non-squamous non-small cell lung cancer (NSCLC) in a phase 3 trial.
ImmuPharma said that additional analysis from its phase III trial of Lupuzor in patients with systemic Lupus erythematosus (SLE) has demonstrated positive results in the Europe cohort.
Midatech Pharma has commenced dosing in its first-in-human study with MTX110 for the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive form of childhood brain cancer.
AstraZeneca’s oncology immunotherapy Imfinzi (durvalumab) met the second primary endpoint of overall survival in the phase III trial for unresectable stage III non-small cell lung cancer (NSCLC).
Midatech has commenced initial dosing in the first in-human study of its sustained release product Q-Octreotide (MTD201) for the treatment of carcinoid cancer and acromegaly.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.